NasdaqCM - Nasdaq Real Time Price USD

Orgenesis Inc. (ORGS)

0.5190 +0.0118 (+2.33%)
At close: April 23 at 4:00 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Ms. Vered Caplan M.Sc. Chairperson of the Board, CEO & President 341.38k -- 1969
Prof. Sarah Ferber Ph.D. Founder & Chief Scientific Officer 268.32k -- 1954
Mr. Victor Miller CFO, Secretary & Treasurer -- -- 1970
Pierre Lammeretz Interim Chief Operating Officer -- -- --
Dr. Shimon Hassin Ph.D. Chief Technology Officer -- -- --
Mr. Evan Fishman Chief Financial Officer of Orgenesis Biotech -- -- --
Mr. Joseph Carpinelli Chief Financial Officer of Octomera -- -- --

Orgenesis Inc.

20271 Goldenrod Lane
Germantown, MD 20876
United States
480 659 6404 https://orgenesis.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
146

Description

Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.

Corporate Governance

Orgenesis Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 08, 2024 - May 13, 2024
Orgenesis Inc. Earnings Call

Related Tickers

PYPD PolyPid Ltd.
4.4845
-0.12%
 
CLGN CollPlant Biotechnologies Ltd.
5.40
+2.27%
 
DYAI Dyadic International, Inc.
1.4900
-2.61%
 
CAMX.ST Camurus AB (publ)
484.60
+0.29%
 
APTCF Advanced Proteome Therapeutics Corporation
0.0002
0.00%
 
SIGY Sigyn Therapeutics, Inc.
5.75
0.00%
 
CRPOF Ceapro Inc.
0.1845
0.00%
 
BIO.DE Biotest Aktiengesellschaft
41.60
0.00%
 
IVBXF Innovent Biologics, Inc.
4.3500
0.00%
 
MNPR Monopar Therapeutics Inc.
0.6500
+2.85%